Xenon Pharmaceuticals reported positive Phase III results for Azetukalner at the American Academy of Neurology annual meeting, potentially shifting focal epilepsy treatment. Learn more.
Epilepsy Agency of the Big Bend (EABB)
Serving the Big Bend
Xenon Pharmaceuticals reported positive Phase III results for Azetukalner at the American Academy of Neurology annual meeting, potentially shifting focal epilepsy treatment. Learn more.
